Inebilizumab

From WikiMD.org
Jump to navigation Jump to search

Inebilizumab

Inebilizumab (pronounced as in-uh-bil-iz-yoo-mab) is a monoclonal antibody designed for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

Etymology

The name "Inebilizumab" is derived from the International Nonproprietary Names (INN), where "Ine-" refers to immune, "-bili-" refers to the target of the drug, which is B cells, and "-zumab" is a suffix used in names of humanized monoclonal antibodies.

Usage

Inebilizumab is used for the treatment of NMOSD, a rare, lifelong, and debilitating autoimmune disease of the central nervous system, affecting the optic nerves and spinal cord. Inebilizumab is specifically used in patients who are anti-aquaporin-4 (AQP4) antibody positive.

Mechanism of Action

Inebilizumab works by binding to the CD19 protein on the surface of B cells, a type of white blood cell, and induces their depletion. This reduces the autoimmune response and prevents damage to the nervous system.

Related Terms

  • Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
  • Neuromyelitis optica spectrum disorder (NMOSD): A rare, lifelong, and debilitating autoimmune disease of the central nervous system.
  • Aquaporin-4 (AQP4): A protein that forms a pore in the cell membrane and primarily functions to conduct water molecules in and out of the cell.
  • CD19: A protein found on the surface of B cells, a type of white blood cell.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski